The FLIPI24 calculates the probability (%) of event (progression, re-treatment, transformation, or death) within the first two years after starting frontline immunochemotherapy. The model assumes CD20 antibody plus CHOP or bendamustine based chemotherapy with a 50% likelihood of CD20 antibody maintenance. Model estimates based on uncommon clinical scenarios are subject to greater variance and should be interpreted with caution. The model data are from the FLIPI24 Consortium, which is comprised of patient data from 10 international cohorts. The survival curves are based on the observed outcomes from the FLIPI24 Consortium dataset for patients with the estimated likelihood of event +/- 5%.
Citation: MJ Maurer et al, FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma. ASH Annual Meeting 2022, Abstract 953
Please follow the link below to find our FLIPI24 Risk Calculator